drugset / Trial / NCT07275242

A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor

NCT07275242

Phase 1 Recruiting 107 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study is being conducted to evaluate the pharmacokinetics , safety, tolerability and efficacy in patients with solid tumor.

Timeline

Start
2025-12-23
Primary completion
2027-06
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Trastuzumab Rezetecan Monoclonal antibody Subcutaneous

Indications